Actuate Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
ACTU
- Share Price
-
$0.31
- (As of Thursday Closing)
Actuate Therapeutics General Information
Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Contact Information
Website
www.actuatetherapeutics.comCorporate Office
- 1751 River Run
- Suite 400
- Fort Worth, TX 76107
- United States
Corporate Office
- 1751 River Run
- Suite 400
- Fort Worth, TX 76107
- United States
Actuate Therapeutics Timeline
Actuate Therapeutics Stock Performance
As of 12-Nov-2026, Actuate Therapeutics’s stock price is $0.31. Its current market cap is $16.3M with 55M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.31 | $0.30 | $0.29 - $7.90 | $16.3M | 55M | 427K | -$0.87 |
Actuate Therapeutics Financials Summary
As of 30-Jun-2026, Actuate Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 28,473 | 125,324 | 141,948 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,773) | (22,495) | (27,489) | (25,054) |
| Net Income | (20,454) | (22,228) | (27,285) | (24,745) |
| Total Assets | 5,199 | 14,036 | 9,318 | 2,996 |
| Total Debt | 0 | 0 | 0 | 988 |
Actuate Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Actuate Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Actuate Therapeutics Comparisons
Industry
Financing
Details
Actuate Therapeutics Competitors (62)
One of Actuate Therapeutics’s 62 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Actuate Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Actuate Therapeutics Patents
Actuate Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128597-A1 | Pharmaceutical compositions comprising combinations of elaraglusib and other therapeutic agents for the treatment of cancer | Pending | 13-Dec-2024 | ||
| WO-2026107416-A1 | Single dosage forms containing elraglusib and at least one other active ingredient | Pending | 18-Nov-2024 | ||
| WO-2025221600-A1 | Biomarkers for use in pancreatic cancer treatment | Pending | 15-Apr-2024 | ||
| WO-2025221600-A9 | Biomarkers for use in pancreatic cancer treatment | Pending | 15-Apr-2024 | ||
| WO-2025183906-A1 | Biomarkers for use in cancer therapy | Pending | 01-Mar-2024 | A61P35/00 |
Actuate Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Actuate Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Actuate Therapeutics FAQs
-
When was Actuate Therapeutics founded?
Actuate Therapeutics was founded in 2015.
-
Where is Actuate Therapeutics headquartered?
Actuate Therapeutics is headquartered in Fort Worth, TX.
-
What is the size of Actuate Therapeutics?
Actuate Therapeutics has 16 total employees.
-
What industry is Actuate Therapeutics in?
Actuate Therapeutics’s primary industry is Drug Discovery.
-
Is Actuate Therapeutics a private or public company?
Actuate Therapeutics is a Public company.
-
What is Actuate Therapeutics’s stock symbol?
The ticker symbol for Actuate Therapeutics is ACTU.
-
What is the current stock price of Actuate Therapeutics?
As of 12-Nov-2026 the stock price of Actuate Therapeutics is $0.31.
-
What is the current market cap of Actuate Therapeutics?
The current market capitalization of Actuate Therapeutics is $16.3M.
-
Who are Actuate Therapeutics’s competitors?
Marengo Therapeutics, Kite Pharma, Carisma Therapeutics, Inovio Pharmaceuticals, and CytomX Therapeutics are some of the 62 competitors of Actuate Therapeutics.
-
What is Actuate Therapeutics’s annual earnings per share (EPS)?
Actuate Therapeutics’s EPS for 12 months was -$0.87.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
